Get the Stockscreener App
1.05
1.94%
0.02
After Hours:
1.04
-0.01
-0.95%
Icecure Medical Ltd stock is traded at $1.05, with a volume of 165.81K.
It is up +1.94% in the last 24 hours and down -17.32% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
165.81K
Relative Volume:
0.65
Market Cap:
$59.40M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-3.75
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
-0.94%
1M Performance:
-17.32%
6M Performance:
+26.17%
1Y Performance:
-0.94%
1-Day Range:
$0.99
$1.07
1-Week Range:
$0.8901
$1.14
52-Week Range:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.05 | 62.13M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Icecure Medical Ltd Stock (ICCM) Latest News
H.C. Wainwright maintains Buy on IceCure Medical, target at $2.50 By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on IceCure Medical, target at $2.50 - Investing.com
IceCure Medical’s (ICCM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ... - Yahoo
Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market Challenges - GuruFocus
ICCM: HC Wainwright & Co. Reiterates Buy Rating with $2.50 Price Target | ICCM Stock News - GuruFocus
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2025 Earnings Call Transcript - Insider Monkey
IceCure Medical outlines post-market study plan for ProSense amid FDA engagement and prepares for US commercial launch - MSN
IceCure Medical reports 2% revenue drop in Q1 2025 - Medical Buyer
IceCure Medical Reports Q1 2025 Financial Results - TipRanks
IceCure Medical’s Earnings Call: Optimism Amid Challenges - TipRanks
Transcript : IceCure Medical Ltd, Q1 2025 Earnings Call, May 28, 2025 - marketscreener.com
Icecure Medical Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
IceCure (ICCM) Q1 2025 Earnings Call Transcript - The Globe and Mail
IceCure (ICCM) Q1 2025 Earnings Call Transcript - The Motley Fool
IceCure Medical Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ICECURE MEDICAL Earnings Results: $ICCM Reports Quarterly Earnings - Nasdaq
IceCure's Breakthrough Breast Cancer Treatment Nears FDA Decision, Targets 46,000 Patient Market - Stock Titan
Icecure Medical Ltd (ICCM) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 - Nasdaq
IceCure Medical Secures $2 Million Bridge Loan from Epoch - TipRanks
IceCure Medical (ICCM) Expected to Announce Earnings on Tuesday - Defense World
IceCure Medical’s Shareholders Approve Key Agenda Items at Special Meeting - TipRanks
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - marketscreener.com
FY2025 EPS Estimates for IceCure Medical Boosted by Analyst - Defense World
IceCure Receives High Level of Interest from Breast Surgeons at - GuruFocus
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation - PR Newswire
Breast Cancer Treatment Breakthrough: Surgeons Rally Behind IceCure's Freezing Technology as FDA Approval Nears - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Shares Acquired by Geode Capital Management LLC - Defense World
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America - Barchart.com
IceCure Medical reports on FDA meeting for ProSense Cryoablation - TipRanks
ICCM Advances ProSense Approval with FDA Interface | ICCM Stock News - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Pat - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer - PR Newswire
FDA Clears Path for Revolutionary Breast Cancer Treatment: ProSense Set to Transform Care for 46,000 Patients - Stock Titan
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - GuruFocus
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems - marketscreener.com
Comparing Biotricity (NASDAQ:BTCY) and IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - StreetInsider
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation | ICCM Stock News - GuruFocus
IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell? - Defense World
IceCure Medical Announces Special Shareholder Meeting for May 2025 - TipRanks
FY2027 EPS Estimates for IceCure Medical Reduced by Analyst - Defense World
IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright - Defense World
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):